Citations

Clear

2 citation(s) found for "Schiller, Thomas M".

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
Haley, Connie A. , Ashkin, David , Peloquin, Charles A. , Cegielski, J. Peter , Andrino, Barbara B, Burgos, Marcos, Caloia, Lori A, Chen, Lisa , Colón‐Semidey, Angel, DeSilva, Malini B. , Dhanireddy, Shireesha , Dorman, Susan E. , Dworkin, Felicia , Hammond-Epstein, Heidi, Easton, Alice V. , Gaensbauer, James , Ghassemieh, Bijan J., Gómez, María Elena, Horné, David , Jasuja, Supriya , Jones, Betsy A., Kaplan, Leonard J., Khan, Asharaf Edward, Kracen, Elizabeth, Labuda, Sarah M. , Landers, Karen M., Lardizabal, Alfred , Lasley, Maria T, Letzer, David, Lopes, Vinicius K, Lubelchek, Ronald , Macias, C. Patricia, Mihalyov, Aimee, Misch, Elizabeth Ann , Murray, Jason A., Nilsen, Diana , Ninneman, M.J., Ogawa, Lynne, Oladele, Alawode, Overman, Melissa C, Ritger, Kathleen A., Rowlinson, Marie‐Claire , Sabuwala, Nadya, Schiller, Thomas M, Schwartz, Lawrence E., Spitters, Christopher, Thomson, Douglas B, Tresgallo, Rene Rico, Valois, Patrick , Goswami, Neela D. , Group, for the BPaL Implementation, Agraz-Lara, Rocio, Ahmed, Amina , Alvarez, Ana , Armitage, Lisa, Belknap, Robert , Bravo, Mary, Brode, Sarah K. , Burden, Elizabeth, Burzynski, Joseph , Caplan‐Shaw, Caralee , Castro, Ken, Chorba, Terry, Cook, Victoria , Cruz, Andrea T. , Dasgupta, Shom, Dhingra, Sonia, Elmore, Ellen, Erwin, Frank, Escuyer, Vincent, Fiske, Christina T. , Gadkowski, Beth, Henestroza, Germán, Higashi, Julie, Keh, Chris , Khalil, Amanda , Kigonya, Lilian, Lauzardo, Michael , Morris, Sapna Bamrah , Nabity, Scott A. , Oxtoby, Margaret J., Patrawalla, Amee , Raftery, Ann, Reed, Caitlin , Rock, Brian, Russo, Kelly, Sahini, Harleen, Saleeb, Paul , Santos, Roberto P. , Seaworth, Barbara , Shaw-Kaikai, Joanna, Starke, J R, Stout, Jason E. , Stubblefield, Wesley, Temesgen, Zelalem , Thomas, Keziah, Urbine, Daniel , Warkentin, Jon, Webb, Risa M. , Wortham, Johnathan, Yu, and Salinia, Altman, C, Hafiz, Irfan, Prabhakar, Deepa, Bowler, William, Gaensbauer, James T , Peloquin, Charles A , Schechter, Marcos C , Narita, Masahiro , Ray, Susan M , Group, for the BPaL Implementation, Alvarez, Ana, Armitage, Lisa, Barry, Pennan M. , Bernardo, John , Connors, William J. A. , Daley, Charles L. , Dobbs, Thomas E. , Escuyer, Vincent , Katrak, Shereen S. , Munsiff, Sonal S. , Phillips, Allison, Stubblefield, Wes, Thomas, Keziah, Tornheim, Jeffrey A. , Upton, Caryn M. , Wang, Shuhua , Wilson, John , Altman, Claudia

Mayo Clinic

Clinical Infectious Diseases | May 30, 2023 | Volume: 77 | Issue: 7 | Pages: 1053-1062

10.1093/cid/ciad312 | PMID 37249079 Get It

Abstract Background Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
Recurrent vomiting and ethylmalonic aciduria associated with rare mutations of the short‐chain acyl‐CoA dehydrogenase gene
Seidel, J., Streck, S., Bellstedt, K., Vianey‐Saban, Christine , Vockley, Jerry , Korall, H, Roskos, Martin, Deufel, Thomas , Trefz, K. F., Sewell, A, Kauf, K., Zintl, Fritz, Lehnert, W., Gregersen, N. , Pedersen, Christina B.

Mayo Clinic

Journal of Inherited Metabolic Disease | September 12, 2003 | Volume: 26 | Issue: 1 | Pages: 37-42

10.1023/a:1024019311933 | PMID 12872838 Get It

AbstractSummary: We report identification of short‐chain acyl‐CoA dehydrogenase (SCAD) deficiency in a 12‐year‐old boy who suffered from recurrent attacks of vomiting once or twice a year from infancy. Growth and development were normal and there were no muscular symptoms. Metabolic screening was performed during a hospitalization at 8 years of age and revealed an increased excretion of ethylmalonic acid (EMA; 45–80 mmol/mol creatinine, normal 0.2–6.6), suggesting a degradation defect of short‐chain fatty acids. An increased n‐butyrylcarnitine was found in freshly collected serum (0.9 µmol/L; normal <0.4) but not in dry blood spots. Neither of the frequent SCAD gene variants 625G>A and 511C>T was present, but direct sequencing of the promoter and coding regions of the SCAD gene revealed that the patient had mutations on both alleles: 417G>C (Trp115Cys) and 1095G>T (Gln341His). Neither mutation has been described before in compound heterozygosity or homozygosity. Enzymatic investigations subsequently confirmed a defect of SCAD in both fibroblasts and muscle extracts. Furthermore, expression studies of both mutations demonstrated impaired enzyme function or structure. To our knowledge, this case is the first description of a patient with proven SCAD deficiency presenting with recurrent emesis but without other symptoms, and emphasizes the wide clinical phenotype of this disorder.